Sarepta Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-50.7M | $-267.3M | $-220.0M | $-135.8M | $-112.0M | $-121.3M | $-2.3M | $-32.2M |
| Depreciation & Amortization | $8.1M | $5.6M | $5.2M | $3.7M | $1.3M | $1.5M | $1.3M | $1.5M |
| Depreciation | $6.4M | $5.0M | $4.7M | $3.2M | $800.0K | $1.0M | $800.0K | $1.2M |
| Amortization | $1.1M | $29.0K | — | — | — | — | — | — |
| Stock-Based Compensation | $30.5M | $30.0M | $32.1M | $20.3M | $11.1M | $3.1M | $3.1M | $3.2M |
| Net Cash from Operating Activities | $-232.0M | $-245.8M | $-149.5M | $-128.5M | $-64.7M | $-29.7M | $-23.7M | $-15.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $12.0M | $5.3M | $3.4M | $25.4M | $2.4M | $108.0K | $1.2M | $832.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-178.8M | $-90.2M | — | — | $-11.7M | $-1.1M | $-2.3M | $-2.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $888.1M | $378.1M | — | — | $145.7M | $178.6M | $32.3M | $2.5M |
| Net Change in Cash | $477.3M | $42.1M | $6.8M | $-183.4M | $69.3M | $147.8M | $6.3M | $-14.7M |
| Free Cash Flow | $-244.0M | $-251.2M | $-152.9M | $-154.0M | $-67.1M | $-29.8M | $-24.9M | $-16.0M |